首页> 外文学位 >In situ forming oral controlled release drug delivery formulations (ISFOF).
【24h】

In situ forming oral controlled release drug delivery formulations (ISFOF).

机译:原位形成口服控释药物递送制剂(ISFOF)。

获取原文
获取原文并翻译 | 示例

摘要

Novel oral drug delivery technologies have emerged and expanded into different drug delivery systems with different drug release mechanisms in the last few decades. Sophisticated instrumentation, modern mathematical models and computational power have revolutionized the entire process of formulation and development of drug delivery systems, and advanced the concept of drug delivery from a simple pill to a programmable, time controlled smart system. In situ forming oral controlled release formulation is a new technology in the field of oral controlled release delivery systems.; The concept of in situ forming devices (ISFD) entered the pharmaceutical field in the early 1980s as parenteral controlled release dosage forms. In last decade, this technology has grown significantly due to their potential advantages compared to the traditional parenteral controlled release dosage forms. However, a review of literature revealed that there are not many publications describing the usage of this technology for oral controlled release formulations. Therefore, the objective of this study was to develop novel in situ forming oral controlled release formulations that can control the drug release up to 24 hours.; In this project, preliminary studies were performed to ascertain the physical compatibility of different solvents with hard gelatin capsules. In addition, a combination of appropriate polymers and solvents were selected such that they could form a drug-loaded gel at the process temperature of 60-70°C, and the gel could convert into a rigid mass upon exposure to dissolution fluid at body temperature. The drug release mechanism from this rigid mass was controlled by different formulation factors such as different polymer grades, polymer concentrations, hydrophobicity or hydrophilicity of solvents, different drug loadings, and physicochemical properties of additional excipients. After evaluating different formulation factors, Ethocel RTM 10 FP and triethyl citrate (TEC) were selected for further studies using propranolol hydrochloride as a model drug. A polynomial correlation between viscosity of the blank gels and drug release profiles was also obtained. The drug release mechanism was investigated by performing solvent leaching studies.; The drug release profiles were optimized using different grades of polyethylene glycols (PEGs). Phase diagrams of ternary mixtures of ethylcellulose, PEG and TEC were obtained and used for optimization of drug release. The phase diagrams showed that addition of higher molecular weight of PEGs increased the phase separation and caused precipitation of ethylcellulose from the ternary mixtures. The effect of different grades and concentrations of PEGs in novel oral controlled release gel formulations were also investigated. In conclusion, the in situ forming oral controlled release formulations were successfully developed and the formulations were able to control the release of propranolol hydrochloride up to 24 hours.
机译:在过去的几十年中,新型口服药物递送技术已经出现并扩展到具有不同药物释放机制的不同药物递送系统中。先进的仪器,现代数学模型和计算能力彻底改变了药物输送系统的配制和开发过程,并使药物输送的概念从简单的药丸变成了可编程的,时间控制的智能系统。原位形成口服控释制剂是口服控释递送系统领域中的一项新技术。原位形成装置(ISFD)的概念以肠胃外控释剂型在1980年代初进入制药领域。在过去的十年中,由于其与传统的肠胃外控释剂型相比具有潜在的优势,因此该技术得到了显着发展。然而,文献综述显示,没有太多出版物描述该技术用于口服控释制剂的用途。因此,本研究的目的是开发新的原位形成口服控释制剂,该制剂可以控制药物释放长达24小时。在该项目中,进行了初步研究,以确定不同溶剂与硬明胶胶囊的物理相容性。另外,选择合适的聚合物和溶剂的组合,使得它们可以在60-70°C的加工温度下形成载药凝胶,并且该凝胶在人体温度下暴露于溶解液中时可以转化为刚性物质。从这种刚性物质释放药物的机制是由不同的配方因素控制的,例如不同的聚合物等级,聚合物浓度,溶剂的疏水性或亲水性,不同的药物负载量以及其他赋形剂的理化性质。在评估了不同的配方因素后,选择Ethocel RTM 10 FP和柠檬酸三乙酯(TEC),以盐酸普萘洛尔作为模型药物进行进一步研究。还获得了空白凝胶的粘度和药物释放曲线之间的多项式相关性。通过进行溶剂浸出研究来研究药物释放机理。使用不同等级的聚乙二醇(PEG)优化了药物释放曲线。获得了乙基纤维素,PEG和TEC的三元混合物的相图,并将其用于优化药物释放。相图显示,添加更高分子量的PEG会增加相分离,并导致乙基纤维素从三元混合物中沉淀出来。还研究了不同等级和浓度的PEG在新型口服控释凝胶制剂中的作用。总之,成功开发了原位形成的口服控释制剂,该制剂能够控制盐酸普萘洛尔的释放长达24小时。

著录项

  • 作者

    Trivedi, Namrata R.;

  • 作者单位

    The University of Tennessee Health Science Center.$bPharmaceutical Sciences.;

  • 授予单位 The University of Tennessee Health Science Center.$bPharmaceutical Sciences.;
  • 学科 Health Sciences Pharmacy.
  • 学位 Ph.D.
  • 年度 2008
  • 页码 106 p.
  • 总页数 106
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药剂学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号